Industry

Lupin, Tenpoint Therapeutics Partner to Commercialize Yuvezzi in U.K. and European Markets

Vision Monday4d ago1 min read

MUMBAI; NAPLES, Fla.; WARREN, N.J.; AMSTERDAM; LONDON—Global pharma company Lupin Limited (Bloomberg: LPCIN) has announced that VISUfarma B.V., a wholly owned subsidiary of Lupin, has inked an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited, granting VISUfarma the exclusive rights to commercialize, market, promote, distribute, and sell Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% within the European Union, the U.K., Switzerland, Norway and Iceland. A once-daily, dual-agent eye drop, Yuvezzi is indicated for the treatment of presbyopia in adults.

Read full article on Vision Monday

AI Summary

Quick Take

Lupin’s subsidiary VISUfarma has entered an exclusive licensing agreement with Tenpoint Therapeutics to commercialize Yuvezzi, a once-daily dual-agent eye drop for presbyopia, in the UK and European markets. The solution combines carbachol (2.75%) and brimonidine tartrate (0.1%) to provide a pharmacological option for adult patients seeking near-vision correction.

Why It Matters

This partnership marks a significant expansion of pharmacological presbyopia treatments into the European and UK markets, where demand for non-surgical alternatives to reading glasses is high. By utilizing a dual-agent formulation, Yuvezzi aims to optimize the miotic effect of carbachol while leveraging brimonidine, which may differentiate its clinical profile from single-agent miotics. For practitioners, this represents a shift toward medical management of a condition traditionally handled solely through optical or surgical means, requiring a new approach to patient counseling and refractive care.

Key Details

VISUfarma (a Lupin subsidiary) holds exclusive rights to commercialize, market, promote, and distribute Yuvezzi in the EU, UK, Switzerland, Norway, and Iceland.
Yuvezzi is a fixed-dose combination of carbachol 2.75% and brimonidine tartrate 0.1%.
The treatment is indicated for the treatment of presbyopia in adults and is designed for once-daily administration.
The agreement was signed with Visus Therapeutics Inc., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited.
The deal covers major European territories, signaling a broad commercial push for pharmacological presbyopia correction outside the U.S.

Practice Implications

Clinicians in the UK and Europe should prepare to integrate pharmacological presbyopia management into their refractive toolkit. As Yuvezzi enters these markets, practitioners will need to identify appropriate candidates who desire spectacle independence for near tasks and monitor for the specific efficacy and safety profile of this dual-agent carbachol/brimonidine combination.

Who's Affected

OptometristsOphthalmologistsPractice OwnersRefractive Surgeons

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.